REMox TB Trial Paves the Way for 21st Century TB Drug Trials
In 2008, TB Alliance launched the first Phase 3 clinical trial of a new TB drug in four decades. The
ZebiAI and TB Alliance Announce Collaboration to Apply ML-Driven Discovery Platform to Tuberculosis Targets
WALTHAM, Mass., February 1, 2021 – ZebiAI, Inc., a biotech company focused on improving human health by powering machine learning (ML) to
New Report Reveals that R&D Partnerships Serving Neglected Communities have Produced Dozens of Life-Saving Innovations Since 2010
NEW YORK (28 January 2021)—The public-private initiatives that contributed to COVID-19 vaccine and drug development have showcased a model for
TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study
NEW YORK (December 15, 2020)—TB Alliance announced that on December 1, 2020 the first dose was administered to a patient
Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis
New Clinical Access Program to Expand Access to Tuberculosis Treatment Pretoria, 10 December 2020—TB Alliance welcomes the Wits Health Consortium
TB Alliance is Honored to Accept the Prix Galien Award for Best Pharmaceutical Agent
NEW YORK (October 30, 2020)—At the Prix Galien Awards Ceremony on Thursday, October 29, The Galien Foundation named pretomanid the
TB Alliance with the Support of the Republic of Korea Announce Initiative to Broaden Adoption and Scale Up of New Treatments for Drug-Resistant Tuberculosis (TB)
LIFT-TB to increase treatment completion rates for drug-resistant TB, focusing on seven high-burden Southeast and Central Asian countries that shoulder
Building Global Capacity for Modern TB Treatment Research
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
With Progress against TB in Jeopardy, New and Improved Tools Are More Urgent than Ever
NEW YORK (October 14, 2020)—The World Health Organization’s Global Tuberculosis (TB) Report 2020 confirms that efforts to track and treat TB
One Year Since U.S. Approval, Accelerating Access to New TB Therapy
PRETORIA — Today marks the one year anniversary of the US FDA’s approval of pretomanid as part of the BPaL